GlassScriptPhysician profile
Andrew R Vogel
NPI 1851783245
$6,917.08
in general payments reported to CMS, 2019-2025
28 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $17.22 · 2021: $1,159 · 2022: $1,194 · 2023: $1,774 · 2024: $1,059 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Travel and Lodging: $918 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.09 |
| Travel and Lodging | $917.72 |
| Education | $187.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,641.26 | 2021-2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $996.42 | 2021-2025 | Nucala, Trelegy Ellipta |
| Olympus Corporation of The Americas | $946.59 | 2023 | Spiration Valve System, Single Use Suction Valve (Sterile) |
| Genzyme Corporation | $835.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $733.87 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $523.16 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.39 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $161.83 | 2021-2025 | Arikayce, Brinsupri |
| Galvanize Therapeutics, INC | $133.25 | 2023-2025 | Aliya System |
| Grifols USA, LLC | $125.07 | 2022-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $71.21 | 2022-2024 | Xolair, Esbriet |
| Vifor Pharma, INC. | $56.24 | 2024-2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $52.46 | 2021-2025 | Eohilia, Glassia |
| Inogen, INC. | $48.41 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Verona Pharma, INC. | $46.81 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $36.68 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $31.32 | 2022-2023 | Nuzyra |
| Lilly USA, LLC | $24.26 | 2021 | |
| Baxter Healthcare | $20.59 | 2022 | |
| Amgen INC. | $19.08 | 2024 | Tezspire |
| Olympus America INC. | $19.00 | 2025 | Spiration Valve System |
| Masimo Corporation | $18.43 | 2025 | Set and Rainbow Set |
| Pulmonx Corporation | $18.03 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abbott Laboratories | $17.22 | 2020 | |
| La Jolla Pharmaceutical Company | $17.03 | 2025 | Giapreza |
| Pfizer INC. | $16.10 | 2025 | |
| Gilead Sciences, INC. | $13.39 | 2021 | |
| Merck Sharp & Dohme LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.